glp-1 heart muscle Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies How GLP-1 Medications Reduce Heart

Johnson-Rabbett says

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity

For a broader overview of weight loss peptides, see our best peptides for weight loss guide

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al

While clinical evidence is still emerging, GLP-1s potential dual ability to reduce the risk of comorbidities and stabilize patients with fewer additional drugs positions them as a cornerstone of modern diabetes care

Your provider at Pure Med Spa Chicago can guide you on the best dosing schedule to minimize nausea